4.8 Review

Invasive Candidiasis

Journal

NEW ENGLAND JOURNAL OF MEDICINE
Volume 373, Issue 15, Pages 1445-1456

Publisher

MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMra1315399

Keywords

-

Funding

  1. Cidara
  2. Pfizer
  3. Astellas
  4. Merck
  5. Gilead
  6. Basilea

Ask authors/readers for more resources

Invasive candidiasis is the most common fungal disease among hospitalized patients in the developed world. Invasive candidiasis comprises both candidemia and deep-seated tissue candidiasis. Candidemia is generally viewed as the more common type of the disease, and it accounts for the majority of cases included in clinical trials. Deep-seated candidiasis arises from either hematogenous dissemination or direct inoculation of candida species to a sterile site, such as the peritoneal cavity (Fig. 1). Mortality among patients with invasive candidiasis is as high as 40%, even when patients receive antifungal therapy. In addition, the global shift in favor of nonalbicans candida species is troubling, as is the emerging resistance to antifungal drugs. During the past few years, new insights have substantially changed diagnostic and therapeutic strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available